
    
      In this open-label study antiretroviral-naive patients are randomized to one of two drug
      regimens:

      Arm I: 141W94 (amprenavir), 1592U89 (abacavir), and Combivir (3TC/AZT tablet). Arm II:
      Nelfinavir and Combivir.
    
  